Christopher R. Flowers

Oncology

210 Ashville Ave # 408
Cary, NC 27518

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 458 publications

Mortality Outcomes Among Long-Term Hodgkin Lymphoma Survivors.

Mortality Outcomes Among Long-Term Hodgkin Lymphoma Survivors.

Journal: JAMA network open

Published: August 18, 2026

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Beyond Static Subtypes in Large B-cell Lymphoma: Context, Plasticity, and Therapeutic Logic.

Journal: Blood cancer discovery

Published: June 02, 2026

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Transforming lymphoma outcomes through international real-world data collaborations: the Global Lymphoma Registry Alliance roadmap.

Journal: Haematologica

Published: April 12, 2026

A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.

A circulating protein signature for predicting severe immune-related adverse events following CAR T-cell therapy in relapsed/refractory lymphoma.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.

Pre-infusion plasma proteomics identifies an endothelial-immune priming signature predictive of severe cytokine release syndrome and neurotoxicity following CAR T-cell therapy in relapsed/refractory lymphoma.

Journal: medRxiv : the preprint server for health sciences

Published: April 10, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Journal: Blood advances

Published: February 23, 2026

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab.

Journal: Blood advances

Published: February 23, 2026

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL.

Journal: Blood neoplasia

Published: February 17, 2026

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

Development and Validation of a Novel Conditional Event-Free Survival Tool in Diffuse Large B-Cell Lymphoma.

Journal: American journal of hematology

Published: February 13, 2026

Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.

Correction: The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.

Journal: Experimental hematology & oncology

Published: February 10, 2026

A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.

A patient derived xenograft repository capturing clinical and molecular heterogeneity of large B-cell lymphoma.

Journal: bioRxiv : the preprint server for biology

Published: February 06, 2026

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.

Diagnosis-to-Treatment Interval Is Associated With Outcomes in Follicular Lymphoma Treated with Immunochemotherapy.

Journal: Blood

Published: January 29, 2026

Showing 1-12 of 458

Last Updated: 09/26/2026